Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide
Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4- yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]- 1-methylcyclohexane-l-carboxamide, alternatively named (1 s,4s)-4-(2-(((3 S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6- trichlorophenyl)amino)-9H-purin-9-yl)- 1 -methylcyclohexane- 1 -carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.